BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 329981)

  • 1. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH; Furnas B
    Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.
    Ahmann DL; Hahn RG; Bisel HF; Eagan RT; Edmonson JH
    Cancer Chemother Rep; 1975; 59(2 Pt 1):451-3. PubMed ID: 1097102
    [No Abstract]   [Full Text] [Related]  

  • 3. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
    Everall JD; Dowd PM
    Cancer Treat Rep; 1979 Jan; 63(1):151-5. PubMed ID: 84710
    [No Abstract]   [Full Text] [Related]  

  • 5. Results with methyl-CCNU and DTIC in metastatic melanoma.
    Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
    Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
    Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; Eagan RT; O'Connell MJ; Frytak S
    Clin Pharmacol Ther; 1976 Jun; 19(6):821-4. PubMed ID: 773589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
    Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of metastatic malignant melanoma (author's transl)].
    Kühböck J; Pehamberger H; Mach K; Diem E; Kokoschka EM; Pötzi P
    Wien Klin Wochenschr; 1978 Dec; 90(24):856-8. PubMed ID: 84441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Carmo-Pereira J; Oliveira Costa F; Pimentel P
    Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
    Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
    Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma.
    De Wasch G; Bernheim J; Michel J; Lejeune F; Kenis Y
    Cancer Treat Rep; 1976 Sep; 60(9):1273-6. PubMed ID: 65222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
    Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
    Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
    Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
    Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
    Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
    Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
    [No Abstract]   [Full Text] [Related]  

  • 18. [Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
    Chauvergne J; Clavel B; Klein T; Pommatau E
    Bull Cancer; 1978; 65(2):107-9. PubMed ID: 359067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas.
    Creagan ET; Hahn RG; Ahmann DL; Edmonson JH; Bisel HF; Eagan RT
    Cancer Treat Rep; 1976 Sep; 60(9):1385-7. PubMed ID: 189922
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Johnson RO; Metter G; Wilson W; Hill G; Krementz E
    Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.